- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: OPC-13013 | OPC-21 | Pletal®
cilostazol is an approved drug (FDA (1999))
Compound class: Synthetic organic
Comment: Cilostazol is a quinolinone-derivative phosphodiesterase (PDE) inhibitor.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: cilostazol
|No information available.
|Summary of Clinical Use
|Used to improve circulatory defecit in the legs which causes intermittent claudication.
|Mechanism Of Action and Pharmacodynamic Effects
|Cilostazol inhibits phosphodiesterase 3A. This results in increased cAMP levels in platelets and blood vessels and leads to inhibition of platelet aggregation and vasodilation, thereby improving circulation.
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)